Which type of breast carcinoma exhibits the least desmoplastic reaction?
Commonest malignancy that can cause splenic metastasis is which of the following?
Inhibin is a tumor marker associated with which of the following tumors?
Which type of breast cancer is most commonly associated with bilateral breast carcinoma?
What is the best assessment for the tendency of colonic carcinoma to metastasize?
In breast carcinoma, prognosis depends best upon -
What is the most common type of anal canal carcinoma?
In which condition is Calretinin primarily used as a diagnostic marker?
Paraneoplastic syndrome Hypercalcemia of malignancy is produced due to ectopic production of which hormone by solid tumors like squamous cell carcinoma?
Which syndrome is associated with an inherited mutation of the p53 tumor suppressor gene?
Explanation: ***Lobular*** - **Lobular carcinoma** tends to be less desmoplastic than other types, characterized by **small, non-cohesive cells** that invade the stroma with minimal reaction [1]. - It is frequently bilateral and can have a subtle histological presentation, making it less likely to elicit a strong desmoplastic response. *Medullary* - **Medullary carcinoma** is associated with a prominent **lymphocytic infiltrate** and notable desmoplastic stromal reaction [1]. - It presents with a large, well-circumscribed mass and often has a more aggressive nature, which contradicts the characteristics of desmoplastic carcinoma. *Tubular* - **Tubular carcinoma** shows abundant desmoplastic stroma, resulting in a firm consistency [2], contrary to the nature of least desmoplastic carcinoma. - It features distinctive tubular structures and is generally considered a subtype with a more significant desmoplastic reaction. *Ductal* - **Ductal carcinoma**, particularly infiltrating ductal carcinoma, often has a strong desmoplastic reaction, leading to significant stromal fibrosis. - This type frequently presents as a hard mass due to the involved desmoplastic response, differing from the lobular type's characteristics. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Liver And Biliary System Disease, pp. 454-456. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Liver And Biliary System Disease, pp. 453-454.
Explanation: ***Correct: Ca. Melanoma*** - **Melanoma** is the **most common primary malignancy** to metastasize to the spleen in autopsy series [1] - Despite splenic metastases being rare overall (2-9% of cancer patients), melanoma has the **highest propensity** for splenic involvement due to its aggressive hematogenous spread pattern [1] - Melanoma can metastasize to virtually any organ, and the spleen is a recognized site with melanoma being the leading primary source - Other common primaries include breast, lung, ovarian, and colorectal cancers *Incorrect: Ca. Pancreas* - While pancreatic cancer can involve the spleen, this typically occurs through **direct extension** due to anatomical proximity rather than true hematogenous metastasis - Pancreatic cancer more commonly spreads to liver, peritoneum, and regional lymph nodes - It is not the most common source of splenic metastases overall *Incorrect: Ca. Stomach* - Gastric cancer can rarely metastasize to the spleen, but this is uncommon - More typical sites of gastric cancer metastasis include liver, peritoneum, lungs, and lymph nodes - Splenic involvement is much less frequent than with melanoma *Incorrect: Ca. Cervix* - Cervical cancer typically spreads by **local extension** and via lymphatics to pelvic and para-aortic nodes - It may involve bladder, rectum, and vagina through direct spread - **Splenic metastases** from cervical cancer are extremely rare and not a characteristic pattern of spread **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Disorders Involving Inflammatory And Haemopoietic Cells, pp. 650-651.
Explanation: ***Granulosa cell tumor (a type of ovarian tumor)*** - **Inhibin** is a polypeptide hormone primarily produced by the **granulosa cells** of the ovary and Sertoli cells of the testis [1]. - Granulosa cell tumors, being composed of granulosa cells, often **overproduce inhibin**, making it a valuable tumor marker for diagnosis, monitoring recurrence, and treatment response [1]. *Serous cystadenoma (a type of ovarian epithelial tumor)* - While serous cystadenomas are common ovarian tumors, they are of **epithelial origin** and typically do not produce inhibin. - Markers like **CA-125** are more commonly associated with epithelial ovarian cancers, though not typically with benign serous cystadenomas. *Krukenberg tumor (a metastatic ovarian tumor)* - Krukenberg tumors are **metastatic neoplasms to the ovary**, most commonly originating from the gastrointestinal tract (especially the stomach). - Their marker profile reflects the primary tumor, and **inhibin is not a typical marker** for these metastatic lesions. *Dysgerminoma (a type of ovarian germ cell tumor)* - Dysgerminomas are **germ cell tumors** of the ovary, analogous to seminomas in males. - Tumor markers associated with dysgerminomas include **lactate dehydrogenase (LDH)**, and sometimes **beta-hCG**, but not inhibin. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Female Genital Tract, pp. 1036-1037.
Explanation: ***Invasive lobular carcinoma*** - **Invasive lobular carcinoma (ILC)** is the type of breast cancer most frequently associated with **bilateral disease**. [1], [2] This is due to its growth pattern, which often involves the widespread infiltration of cells that can occur in both breasts. [2] - ILC cells tend to grow in single-file strands, making them less likely to form a palpable mass or be detected by mammography, leading to a higher chance of multifocal or bilateral involvement. [1] *Ductal carcinoma in situ* - **Ductal carcinoma in situ (DCIS)** is a non-invasive lesion, meaning the cancerous cells are confined to the breast ducts and have not spread into surrounding breast tissue. - While DCIS can be multifocal within the same breast, it is less commonly associated with bilateral synchronous or metachronous disease compared to invasive lobular carcinoma. *Invasive ductal carcinoma* - **Invasive ductal carcinoma (IDC)** is the most common type of invasive breast cancer overall, accounting for 70-80% of all invasive breast cancers. - While IDC can be bilateral, it is less frequently associated with bilateral presentation than invasive lobular carcinoma. Its growth pattern typically forms a distinct mass that is more readily detected. *None of the options* - This option is incorrect because **invasive lobular carcinoma** is indeed a type of breast cancer with a well-established association with bilateral disease. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Liver And Biliary System Disease, pp. 454-455. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Breast, pp. 1068-1069.
Explanation: ***Depth of penetration of bowel wall (T stage)*** - The **depth of tumor invasion** through the bowel wall is the most critical factor reflecting the likelihood of metastasis in colorectal cancer [1]. - Deeper invasion (higher T stage) directly correlates with increased risk of involvement of lymphatics, blood vessels, and adjacent organs, leading to **distant metastasis** [2]. *Size of tumor* - While larger tumor size can sometimes correlate with advanced disease, it is not as reliable a predictor of metastatic potential as the **depth of invasion**. - A small tumor deeply invading the bowel wall can be more aggressive than a large, superficial one. *Carcinoembryonic antigen (CEA) levels* - **CEA levels** are primarily used for monitoring treatment response and detecting recurrence, not for initially assessing the metastatic potential of the primary tumor. - Elevated pre-operative CEA can indicate more advanced disease, but it's not the primary determinant of metastatic risk itself. *Proportion of bowel circumference involved* - The **circumferential involvement** can indicate a more advanced local tumor and greater risk of obstruction, but it is not the most direct predictor of distant metastatic potential [2]. - Lateral spread along the circumference is distinct from the depth of penetration through the wall. *Histological grade of the tumor* - The **histological grade** (differentiation) of the tumor is an important prognostic factor, with poorly differentiated tumors generally having a worse prognosis and higher metastatic risk. - However, the depth of invasion (T stage) is generally considered a more dominant predictor of metastatic tendency in colorectal cancer. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 236-237. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Alimentary System Disease, pp. 374-375.
Explanation: ***Axillary lymphnode status*** - The presence and number of **positive axillary lymph nodes** are the **most significant prognostic factor** in breast carcinoma, as they directly indicate the extent of regional spread [1]. - Involvement of axillary lymph nodes is strongly predictive of a **higher risk of distant metastasis** and generally a poorer prognosis [2]. *Estrogen receptor status* - **Estrogen receptor (ER) status** is an important **predictive marker** for response to hormonal therapy, but it is not the best single indicator of overall prognosis in metastatic disease [2]. - While ER-positive tumors generally have a better prognosis and respond to endocrine therapy, the presence of metastasis itself dictates much of the prognosis. *Size of tumour* - **Tumor size** is a significant prognostic factor for **primary breast cancer**, with larger tumors generally having a worse prognosis [1]. - However, in the context of **metastasis**, the spread to lymph nodes or distant sites becomes a more critical determinant of overall prognosis than the original tumor size. *Site of tumour* - The **site of the primary tumor within the breast** generally has **little independent prognostic value** once metastasis has occurred or is being evaluated. - While certain locations might be associated with variations in lymph node drainage, the actual **lymph node status** is what directly reflects metastatic spread and prognosis. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Breast, pp. 1070-1072. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Liver And Biliary System Disease, pp. 458-459.
Explanation: ***Squamous cell carcinoma*** - This is the most prevalent type of anal canal carcinoma, accounting for over **80% of all anal cancers**. - It arises from the **squamous epithelial cells** lining the anal canal, often linked to **HPV infection**. *Adenocarcinoma* - This type of cancer originates from the **glandular cells** in the upper part of the anal canal or from **anal glands**. - It is a much rarer form of anal cancer compared to squamous cell carcinoma. *Adenoacanthoma* - This is a rare variant of **adenocarcinoma** that also contains foci of benign or malignant squamous differentiation. - It is not the most common type and represents a specific histological subtype. *Papillary carcinoma* - This term describes a **growth pattern** of various carcinomas characterized by finger-like projections or papillae. - It is not a distinct primary type of anal canal carcinoma, but rather a descriptive feature that can be found in some adeno- or squamous cell carcinomas.
Explanation: ***Mesothelioma*** - **Calretinin** is a sensitive marker used specifically for diagnosing **mesothelioma**, particularly in differentiating it from adenocarcinomas [1]. - It is expressed in **mesothelial cells**, making it a crucial tool in immunohistochemical staining for tumor identification [1]. *Hamartoma* - **Hamartomas** typically do not express **calretinin**, and their diagnosis requires different markers based on the tissue type involved. - They are benign and can occur in various organs but do not show mesothelial characteristics. *Chordoma* - **Chordomas** are malignant tumors originating from notochordal remnants, and they are not associated with **calretinin** positivity. - They are usually **mucins-positive** and identified using other specific markers, such as **brachyury**. *Choristoma* - **Choristomas** are benign lesions of ectopic tissue, and like hamartomas, they do not express **calretinin**. - These tumors are often diagnosed based on the specific type of tissue they contain rather than immunohistochemistry. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Lung, p. 731.
Explanation: ***PTHrP*** - **Parathyroid hormone-related protein (PTHrP)** is the most common cause of **humoral hypercalcemia of malignancy**, particularly in **solid tumors** such as squamous cell carcinoma (lung, head and neck), renal cell carcinoma, and breast cancer. - It mimics the actions of parathyroid hormone (PTH), leading to increased **bone resorption** and **renal calcium reabsorption**. - PTHrP binds to the same PTH receptor and activates similar signaling pathways, resulting in elevated serum calcium levels. *Calcitonin* - **Calcitonin** is a hormone that **lowers blood calcium levels** by inhibiting osteoclast activity and increasing renal calcium excretion. - Ectopic production of calcitonin (seen in medullary thyroid carcinoma) would cause **hypocalcemia**, not hypercalcemia. *PGE2* - **Prostaglandin E2 (PGE2)** can contribute to **local bone resorption** in some malignancies through stimulation of osteoclast activity. - However, its role is less prominent and typically involves **local osteolytic** mechanisms rather than systemic humoral effects like PTHrP. *Parathormone* - **Parathormone (PTH)** is produced by the parathyroid glands; true ectopic PTH production by tumors is **extremely rare**. - The primary mechanism of humoral hypercalcemia of malignancy in solid tumors is almost exclusively due to **PTHrP**, not PTH itself.
Explanation: ***Li-Fraumeni syndrome*** - This syndrome is characterized by an inherited mutation in the **TP53 tumor suppressor gene**, which encodes the p53 protein. - Individuals with Li-Fraumeni syndrome have a significantly increased risk of developing various cancers at a young age, including **osteosarcoma**, soft tissue sarcomas, breast cancer, brain tumors, and adrenocortical carcinoma. *Familial adenomatous polyposis syndrome* - This syndrome is caused by an inherited mutation in the **APC tumor suppressor gene**, not p53. - It is characterized by the development of hundreds to thousands of **colorectal adenomatous polyps**, which inevitably progress to colorectal cancer if untreated. *Retinoblastoma syndrome* - This syndrome is caused by an inherited mutation in the **RB1 tumor suppressor gene**, not p53. - It primarily affects the eye, leading to the development of **retinoblastoma**, a malignant tumor of the retina, often in childhood. *Osteosarcoma syndrome* - While osteosarcoma is a common cancer type seen in Li-Fraumeni syndrome, "Osteosarcoma syndrome" itself is not a distinct inherited syndrome specifically defined by a p53 mutation. - **Osteosarcoma** can arise from various genetic predispositions, including Li-Fraumeni syndrome, but it's not the sole defining characteristic of a p53-related syndrome.
Nomenclature and Classification of Tumors
Practice Questions
Characteristics of Benign and Malignant Neoplasms
Practice Questions
Molecular Basis of Cancer
Practice Questions
Carcinogenesis and Carcinogens
Practice Questions
Tumor Progression and Metastasis
Practice Questions
Tumor Markers
Practice Questions
Paraneoplastic Syndromes
Practice Questions
Genetic Basis of Cancer
Practice Questions
Tumor Immunity
Practice Questions
Cancer Epidemiology and Prevention
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free